연구성과로 돌아가기
2021 연구자 정보 (1030 / 1146)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Vidhyavathi, R. M. (Vidhyavathi, RM) |
Alagappa Univ, Dept Bioinformat Sci Campus, Karaikkudi, Tamil Nadu, India |
GPF-7986-2022 Vidhyavathi, Ramasamy |
|
[JCR상위 77.7] Antifungal activity and molecular docking of phenol, 2,4-bis(1,1-dimethylethyl) produced by plant growth-promoting actinobacterium Kutzneria sp. strain TSII from mangrove sediments | SCIE | 77.7 | MICROBIOLOGY | kavithat@alagappauniversity.ac.in; | ||
|
Vijay, Karuppiah (Vijay, K) |
Alagappa Univ, Dept Microbiol, Sci Campus, Karaikkudi, Tamil Nadu, India |
GMW-9090-2022 Karuppiah, Vijay |
0000-0001-7950-7899 Karuppiah, Vijay |
[JCR상위 77.7] Antifungal activity and molecular docking of phenol, 2,4-bis(1,1-dimethylethyl) produced by plant growth-promoting actinobacterium Kutzneria sp. strain TSII from mangrove sediments | SCIE | 77.7 | MICROBIOLOGY | kavithat@alagappauniversity.ac.in; | ||
|
Zhang, Jing (Zhang, J) |
Korea Atom Energy Res Inst, Div Radiat Res, Jeongeup 56212, South Korea |
E-9167-2018 Zhang, Jing |
|
[JCR상위 77.7] Hymenobacter busanensissp. nov., radiation-resistant species isolated from soil in South Korea | SCIE | 77.7 | MICROBIOLOGY | heeyoung@knu.ac.kr; | ||
|
Beach, C. L. (Beach, CL) |
Bristol Myers Squibb, Princeton, NJ USA |
|
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial [JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial |
SCIE | 4.5 |
ONCOLOGY HEMATOLOGY;ONCOLOGY |
fravandi@mdanderson.org; | ||
|
Chevassut, T. (Chevassut, T) |
Brighton & Sussex Med Sch, Brighton, E Sussex, England |
|
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY | |||
|
Dombret, H. (Dombret, H) |
Hop St Louis, AP HP, Hematol, Paris, France Univ Paris, Inst Rech St Louis, Paris, France |
|
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY | |||
|
Figuera, A. (Figuera, A) |
Hosp Univ La Princesa, Madrid, Spain |
|
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY | |||
|
Hiwase, D. (Hiwase, D) |
Royal Adelaide Hosp, Adelaide, SA, Australia |
|
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY | |||
|
La Torre, I (La Torre, I) |
Celgene, Boudry, Switzerland |
|
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY | |||
|
Montesinos, P. (Montesinos, P) |
Hosp Univ Politecn La Fe, Valencia, Spain |
GYU-2673-2022 Montesinos, Pau |
0000-0002-3275-5593 Montesinos, Pau |
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY | |||
|
Musso, M. (Musso, M) |
La Maddalena Casa Cura, Palermo, Italy |
|
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY | |||
|
Pfeilstocker, M. (Pfeilstöcker, M) |
제1저자 | Hanusch Hosp, Vienna, Austria |
AAN-6206-2021 Pfeilstöcker, Michael |
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY | ||
|
Pierdomenico, F. (Pierdomenico, F) |
Portuguese Inst Oncol Lisbon, Lisbon, Portugal |
|
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY | |||
|
Pocock, C. (Pocock, C) |
Kent & Canterbury Hosp, Canterbury, Kent, England |
|
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY | |||
|
Ravandi, F. (Ravandi, F) |
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA |
GOH-3538-2022 Ravandi, Farhad |
|
[JCR상위 77.8] Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial | SCIE | 77.8 | ONCOLOGY |
페이지 이동: